CAT and melanoma: In one trial, catalase-loaded nanoparticles combined with anti-PD-1 therapy for advanced melanoma led to enhanced T cell infiltration and improved overall response rates compared to anti-PD-1 monotherapy (Fig. 12) (Hei et al., 2020).